NKGen Biotech, Inc. Issues Statement on Recent Board Appointments at Majority-Owned Korean Affiliate NKGen Korea Co., Ltd.

Core Viewpoint - NKGen Biotech, Inc. announces recent changes to the Board of Directors of its majority-owned subsidiary, NKGen Biotech Korea, aimed at enhancing governance and supporting growth in the Asia-Pacific region [1][4]. Group 1: Board Changes - NKGen Korea, formerly known as NKMax Co., Ltd., completed a name change on November 21, 2025, and appointed three new board members: Hanhan Xu, Xuan Zhang, and Dr. June H. Lee, each for a three-year term [2]. - Dr. Angie You was appointed to the NKGen Korea Board for a one-year term on August 14, 2025, bringing significant experience in scientific leadership and operations [2][4]. Group 2: Leadership Impact - The new board members are expected to provide valuable guidance and governance as NKGen Korea emerges from rehabilitation and accelerates its NK cell therapy development [4]. - The appointments are seen as a strategic move to strengthen NKGen Korea's leadership and advance its mission across the Asia-Pacific region [4]. Group 3: Company Overview - NKGen Korea is a clinical-stage biotechnology company based in Seoul, South Korea, focused on developing advanced NK cell therapies and commercializing bioreagents and immunodiagnostic technologies [5]. - The company operates a GMP-certified cell therapy manufacturing facility that supports both domestic and international clinical trials and research programs [5].